Evidence map›Paper›PMID 27624129›Full record

ArticlemBio2016

Activation of the DNA Damage Response Is a Conserved Function of HIV-1 and HIV-2 Vpr That Is Independent of SLX4 Recruitment.

Oliver I Fregoso, Michael Emerman

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 45 citations in OpenAlex.

  1. Manipulation of the cell cycle by HIV-1.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. HIV-1 Vif and Vpr cooperatively modulate the cell cycle to maximize per-cell virion production.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. A CRISPR-Cas Cure for HIV/AIDS.International journal of molecular sciences · 2023
    Review
  12. Article
  13. CHAF1A/B mediate silencing of unintegrated HIV-1 DNAs early in infection.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Oliver I FregosoDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA ofregoso@mednet.ucla.edu memerman@fredhutch.org.
Michael EmermanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA ofregoso@mednet.ucla.edu memerman@fredhutch.org.
Fred Hutch Cancer Center · US

Funding

Chromosome Metabolism and Cancer Training GrantT32CA009657 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EISENMAN, ROBERT NEIL · 1991 to 2020
$7.6M
VPR AND HIV INFECTIONR01AI030927 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EMERMAN, MICHAEL · 1991 to 2020
$5.3M
The Evolution of Vpr/Vpx Function in Primate LentivirusesR01GM110570 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EMERMAN, MICHAEL · 2013 to 2016
$1.3M
Regulation of HIV-1 and related lentiviruses by the DNA damage responseK22AI122824 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREGOSO, OLIVER I · 2016 to 2017
$267k
NCI NIH HHS T32 CA009657NIAID NIH HHS K22 AI122824NIAID NIH HHS R01 AI030927NIGMS NIH HHS R01 GM110570
6 · The paper itself

Abstract

unlabelledThere has been extraordinary progress in understanding the roles of lentiviral accessory proteins in antagonizing host antiviral defense proteins. However, the precise primary function of the accessory gene Vpr remains elusive. Here we suggest that engagement with the DNA damage response is an important function of primate lentiviral Vpr proteins because of its conserved function among diverse lentiviral lineages. In contrast, we show that, for HIV-1, HIV-2, and related Vpr isolates and orthologs, there is a lack of correlation between DNA damage response activation and interaction with the host SLX4 protein complex of structure specific endonucleases; some Vpr proteins are able to interact with SLX4, but the majority are not. Using the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 method to knock out SLX4, we formally showed that HIV-1 and HIV-2 Vpr orthologs can still activate the DNA damage response and cell cycle arrest in the absence of SLX4. Together, our data suggest that activation of the DNA damage response, but not SLX4 interaction, is conserved and therefore indicative of an important function of Vpr. Our data also indicate that Vpr activates the DNA damage response through an SLX4-independent mechanism that remains uncharacterized. IMPORTANCE: HIV-1 and HIV-2 belong to a family of viruses called lentiviruses that infect at least 40 primate species, including humans. Lentiviruses have been circulating in primates for at least 5 million years. In order to better fight HIV, we must understand the viral and host factors necessary for infection, adaptation, and transmission of these viruses. Using the natural variation of HIV-1, HIV-2, and related lentiviruses, we have investigated the role of the DNA damage response in the viral life cycle. We have found that the ability of lentiviruses to activate the DNA damage response is largely conserved. However, we also found that the SLX4 host factor is not required for this activation, as was previously proposed. This indicates that the DNA damage response is an important player in the viral life cycle, and yet the mechanism(s) by which HIV-1, HIV-2, and other primate lentiviruses engage the DNA damage response is still unknown.

Indexed as

Cell Cycle CheckpointsDNA DamageCell LineGene Knockout TechniquesHIV-1HIV-2Host-Pathogen InteractionsHumansRecombinasesvpr Gene Products, Human Immunodeficiency VirusRecombinasesSLX4 protein, humanvpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1vpr protein, Human immunodeficiency virus 2

Identifiers

PMID27624129
PMCPMC5021806
OpenAlexW2519807979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.